Follow Us: social media social media social media    Language :           

Motilium® (domperidone): New recommendations to minimise cardiac risks

Date: 4 August 2015

Description:

The NPCB would like to alert healthcare professionals of restrictions to the use of domperidone to minimise the risk of cardiac adverse effects. The indication of domperidone has been tightened, the maximum daily dose restricted to 40mg/day, and new contraindications have been added.Domperidone should be used at the lowest effective dose for the shortest possible duration. The DCAhas issued a directive for all products containing domperidone to update their package inserts with information regarding this safety issue. For further details, please refer to the Direct Healthcare Professional Communication (DHPC) issued by Janssen, a division of Johnson & Johnson Sdn. Bhd., in agreement with NPCB.

qrcode